Glucose metabolism as a target of histone deacetylase inhibitors.

Journal Article (Journal Article)

The therapeutic efficacy of histone deacetylase inhibitors (HDACI) is generally attributed to their ability to alter gene expression secondary to their effects on the acetylation status of transcription factors and histones. However, because HDACIs exhibit similar transcriptional effects in most cells, the molecular basis for their therapeutic selectivity toward malignant cells is largely unknown. In this study, we report that HDACI, of distinct chemotypes, quantitatively inhibit glucose transporter 1 (GLUT1)-mediated glucose transport into multiple myeloma cells through both down-regulation of GLUT1 and inhibition of hexokinase 1 (HXK1) enzymatic activity. Unexpectedly, however, this inhibition of glucose utilization is accompanied by an increase in amino acid catabolism with no increase in fatty acid oxidation. Our findings suggest that an HDACI-induced change in carbon source preference could contribute to the therapeutic efficacy of these drugs by creating a pattern of fuel utilization that is incompatible with rapid tumor growth and survival. Furthermore, these results, which implicate glucose metabolism as a target of HDACI, suggest that caution should be exercised in attributing effects of this class of drug to primary alterations in gene transcription.

Full Text

Duke Authors

Cited Authors

  • Wardell, SE; Ilkayeva, OR; Wieman, HL; Frigo, DE; Rathmell, JC; Newgard, CB; McDonnell, DP

Published Date

  • March 2009

Published In

Volume / Issue

  • 23 / 3

Start / End Page

  • 388 - 401

PubMed ID

  • 19106193

Pubmed Central ID

  • PMC2654518

International Standard Serial Number (ISSN)

  • 0888-8809

Digital Object Identifier (DOI)

  • 10.1210/me.2008-0179


  • eng

Conference Location

  • United States